Literature DB >> 1710516

Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis.

N Kaufman1, J D Page, R A Pixley, R Schein, A H Schmaier, R W Colman.   

Abstract

Activation of the contact system has been documented in severe sepsis and hereditary angioedema, but a sensitive, specific, and quantitative assay for assessing the degree of involvement of this proteolytic enzyme cascade is not yet available. We have developed a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) for the alpha 2-macroglobulin-kallikrein (alpha 2M-Kal) complex using an F(ab')2 derivative of a monospecific polyclonal antibody against alpha 2 M as the capture antibody and a unique murine monoclonal antibody, 13G11, against the heavy chain of kallikrein as the detector antibody. The assay does not detect complexes in normal plasma but reacts with complexes generated by activating normal plasma with dextran sulfate at 4 degrees C in a range of 5 to 375 nmol/L. A close correlation of the ELISA with an amidolytic assay for alpha 2M-Kal was documented. Patients with sepsis syndrome but negative bacterial blood cultures did not show elevated plasma complexes, whereas a majority of those with positive blood cultures did show modest elevation and a single patient with septic shock showed a very high level of alpha 2M-Kal complex. Similarly, a patient with classic hereditary angioedema (HAE) showed increased concentration of complexes on three separate occasions during attacks but normal levels between attacks. Two other HAE patients did not show elevated levels at quiescent periods. The ELISA for alpha 2M-Kal appears to be sensitive, specific, and quantitative, and it can be used to reflect the degree of contact system activation in human sepsis and in HAE attacks.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710516

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

Review 1.  Drugs derived from phage display: from candidate identification to clinical practice.

Authors:  Andrew E Nixon; Daniel J Sexton; Robert C Ladner
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  The plasma kallikrein-kinin system in sepsis, inflammatory arthritis, and enterocolitis.

Authors:  R W Colman; R B Sartor; A A Adam; R A DeLa Cadena; A Stadnicki
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

4.  Activated factor XI inhibits chemotaxis of polymorphonuclear leukocytes.

Authors:  Asako Itakura; Norah G Verbout; Kevin G Phillips; Robert H Insall; David Gailani; Erik I Tucker; Andras Gruber; Owen J T McCarty
Journal:  J Leukoc Biol       Date:  2011-08-01       Impact factor: 4.962

5.  Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor.

Authors:  D Kolte; Jw Bryant; D Holsworth; J Wang; P Akbari; Gw Gibson; Z Shariat-Madar
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

6.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

7.  Binding of platelet-derived growth factor-BB and transforming growth factor-beta 1 to alpha 2-macroglobulin in vitro and in vivo: comparison of receptor-recognized and non-recognized alpha 2-macroglobulin conformations.

Authors:  K P Crookston; D J Webb; J Lamarre; S L Gonias
Journal:  Biochem J       Date:  1993-07-15       Impact factor: 3.857

8.  Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model.

Authors:  J P de Boer; A A Creasey; A Chang; J J Abbink; D Roem; A J Eerenberg; C E Hack; F B Taylor
Journal:  Infect Immun       Date:  1993-12       Impact factor: 3.441

9.  Activation of the contact system in lethal hypotensive bacteremia in a baboon model.

Authors:  R A Pixley; R A DeLa Cadena; J D Page; N Kaufman; E G Wyshock; R W Colman; A Chang; F B Taylor
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

Review 10.  C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome induced by high doses of interleukin-2.

Authors:  C E Hack; A C Ogilvie; B Eisele; A J Eerenberg; J Wagstaff; L G Thijs
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.